Mr. Andre Jerome reports

AURORA INTRODUCES MEDICAL CANNABIS PASTILLES FOR PATIENT RELIEF IN AUSTRALIA

Aurora Cannabis Inc., together with subsidiary company MedReleaf Australia, has made available medical cannabis pastilles for doctors to prescribe to patients in Australia. The novel product is produced by Aurora and distributed by MedReleaf Australia, a leading distributor of medical cannabis products with the No. 2 position in the Australian market.

"Australia is the largest nationally legal medical market globally, and as a long-standing supplier to MedReleaf Australia and recently announced parent company, we're eager to support the continued growth and development of the market," said Andre Jerome, executive vice-president of global business development, Aurora. "The introduction of innovative and differentiated products, such as pastilles, and planned upcoming innovation, will provide Australian doctors expanded options for patient care and enhance patient access to the premium medical cannabis they seek," continued Mr. Jerome.

The 30-pack pastilles are available now in three formats including:

• Aurora tetrahydrocannabinol pastilles in watermelon flavour (five milligrams THC);
• Aurora cannabidiol pastilles in peach flavour (10 mg CBD);
• Aurora balanced pastilles in yuzu lemon flavour (five mg THC, 10 mg CBD).

MedReleaf Australia is committed to providing Australian patients with a consistent and reliable supply of superior quality products, including dried flower, resin cartridges and oils, and now pastilles. The new pastille products are available under the Aurora brand, exclusive to MedReleaf Australia. This initial pastille launch will soon be followed by additional options in terms of pack size and potency, as well as future pastille offerings under the IndiMed brand.

"As a company committed to patients and expanding access to medical cannabis under the Australian program, bringing novel innovation to market clearly underscores our status as an industry frontrunner in Australia," said Kristin Viccars, managing director at MedReleaf Australia. "Our predosed pastilles broaden our range of high-quality, medical cannabis offerings and cater to all patient groups who may find the taste of oil or flower undesirable, providing a discreet, portable and cost-effective alternative for those seeking medical cannabis as part of their regime," said Ms. Viccars.

For further information about pastilles, doctors and health care professionals can contact MedReleaf Australia's clinical support team or visit their website.

About Aurora Cannabis Inc.

Aurora is opening the world to cannabis, serving both the medical and consumer markets across Canada, Europe, Australia and South America. Headquartered in Edmonton, Alta., Aurora is a pioneer in global cannabis, dedicated to helping people improve their lives. The company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Tasty's, Being and Greybeard. Medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co., as well as international brands Pedanios, Bidiol, IndiMed and CraftPlant. Aurora also has a controlling interest in Bevo Farms Ltd., North America's leading supplier of propagated agricultural plants. Driven by science and innovation, and with a focus on high-quality cannabis products, Aurora's brands continue to break through as industry leaders in the medical, wellness and adult recreational markets wherever they are launched.

We seek Safe Harbor.